TelyRx Holdings Inc. to Commence Trading on the Toronto Stock Exchange Effective April 7, 2026
Clearwater, Florida--(Newsfile Corp. - April 7, 2026) - TelyRx Holdings Inc. (TSX: TELY) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced that its subordinate voting shares will commence trading on the Toronto Stock Exchange ("TSX") under the ticker symbol "TELY" effective Tuesday, April 7, 2026. This milestone follows the completion of its go-public transaction pursuant to the combination with Apolo V Acquisiti
Soins de santé et hôpitaux, Santé
2026-04-07 7:00 AM EDT | TelyRx
Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets
Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of methadone hydrochloride 5 mg and 10 mg tablets. Methadone tablets are indicated for the management of severe and persistent pain that requires an opioid analgesic that cannot be adequately treated with alternative o
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-02 8:00 AM EDT | Elite Pharmaceuticals, Inc.
Resverlogix Corp. Announces Issuance of MCTO by ASC
Calgary, Alberta--(Newsfile Corp. - April 2, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the issuance of a management cease trade order ("MCTO") by the Alberta Securities Commission (the "ASC") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), following an application made by the Company, and first announced on March 17, 2026 (the "Original Announcement"). The MCTO relates to Resverlogix's default on the prescribed deadl
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-04-02 7:15 AM EDT | Resverlogix Corp.
Adia Nutrition, Inc. Reports Strong Revenue Growth in 2025 Annual Report, Highlighting Transition to Regenerative Medicine and Full SEC Reporting Status
Winter Park, Florida--(Newsfile Corp. - April 1, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions, today announced key highlights from its Form 10-K annual report for the year ended December 31, 2025. The filing marks a pivotal year of operational expansion following the company's successful transition from a dormant shell to an active player in the high-growth regenerative healthcare sector. In 2025, Adi
Soins de santé et hôpitaux, Santé
2026-04-01 10:07 AM EDT | Adia Nutrition Inc.
Envoy Medical Announces First Patients Successfully Reaching 12-Month Endpoint in Pivotal Clinical Trial for Fully Implanted Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - April 1, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, announced that the first three patients implanted in its pivotal clinical trial for the fully implanted Acclaim® cochlear implant have successfully completed their 12-month endpoint visit, marking a key milestone in the study's pr
Biotechnologies, Soins de santé et hôpitaux
2026-04-01 8:00 AM EDT | Envoy Medical, Inc.
Scryb Reports 2026 AGM Results and Welcomes Veteran Capital Markets and Finance Directors
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb" or the "Company") is pleased to announce the results of its Annual General Meeting of shareholders (the "AGM") held on March 31, 2026. All resolutions presented at the AGM received overwhelming shareholder support, with more than 99% of votes cast in favour. This strong approval reflects shareholder confidence in the Company's management team, leadership, refreshed strategy, and long-
Biotechnologies, Soins de santé et hôpitaux, Santé
2026-04-01 7:06 AM EDT | Scryb Inc.
Resverlogix Corp. Provides Bi-Weekly MCTO Status Update
Calgary, Alberta--(Newsfile Corp. - March 31, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") is providing an update on the management cease trade order ("MCTO") application it made to the Alberta Securities Commission (the "ASC") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"). The application remains under review, and no decision has yet been made by the ASC. The Company announced on March 17, 2026 (the "Original Announcement") that
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-03-31 7:09 PM EDT | Resverlogix Corp.
FendX Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - March 31, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, is pleased to provide a corporate update from Dr. Carolyn Myers, the Company's President and CEO. Dear FendX Shareholders, Over the past several months, FendX has achieved meaningful pro
Technologies, Soins de santé et hôpitaux, Santé
2026-03-31 7:00 AM EDT | FendX Technologies Inc.
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply for future clinical trials. The company will manufacture Phio's lead compo
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-30 7:00 AM EDT | Phio Pharmaceuticals Corp.
The Future of Skin Aging May Be Found in The Kitchen: 2026 American Academy of Dermatology Annual Meeting to Highlight Latest Advancements in Skin, Hair, and Nails
Denver, Colorado--(Newsfile Corp. - March 27, 2026) - As interest grows in how lifestyle factors can influence people's appearance, dermatologists are taking a closer look at how diet may affect the internal and structural changes that contribute to the appearance of aged skin. Emerging research on the role of nutrition in skin aging is one of the timely and impactful topics that will be discussed at the 2026 American Academy of Dermatology (AAD) Annual Meeting, held March 27-31 in Denver, Co
Soins de santé et hôpitaux, Santé
2026-03-27 9:00 AM EDT | American Academy of Dermatology
NuGen Files Patent for Ready-to-Fill COP/COC Needle-Free Injection Nozzle, Advancing Prefilled Nozzle Technology
Toronto, Ontario--(Newsfile Corp. - March 25, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"), a leader in needle-free drug delivery, today announced the filing of a new patent covering a Ready-to-Fill (RTF) COP/COC injection nozzle designed specifically for pharmaceutical needle-free applications. The nozzle, which is the subject of a newly filed patent application, represents a novel pharmaceutical packaging component that enables needle-free injection using established ase
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-25 5:15 PM EDT | NuGen Medical Devices Inc.
Governance Professionals of Canada Celebrates 4th Annual Governance Professionals Day, Spotlighting Next Gen Governance Leaders and a TMX Market Close with Ivey Business School
Toronto, Ontario--(Newsfile Corp. - March 25, 2026) - Governance Professionals of Canada (GPC) is proud to celebrate Governance Professionals Day (GP Day) on March 25, marking the fourth nationwide recognition of the essential role governance professionals play in shaping responsible, transparent, and accountable organizations. This year's theme reflects GPC's recent launch of the Next Gen Governance Professionals Initiative, a na
Services bancaires / financiers, Secteur de l’éducation, Soins de santé et hôpitaux, Pétrole et gaz
2026-03-25 10:21 AM EDT | Governance Professionals of Canada
Familywood Releases New Clinical Guide to Support Families Affected by Addiction
Penticton, British Columbia--(Newsfile Corp. - March 25, 2026) - Familywood, a virtual clinical counselling practice dedicated exclusively to families affected by addiction, has released a complimentary, evidence-informed guide designed to support families navigating the complex realities of loving someone with addiction. "Families are often deeply impacted and the least supported in the context of addiction," said Dr. Zach Walsh, Clinical Psychologist and Professor, University of Briti
2026-03-25 10:00 AM EDT | Familywood Family Support Services Inc.
Apolo V Acquisition Corp. Announces Filing of Filing Statement in Connection with Qualifying Transaction
Toronto, Ontario--(Newsfile Corp. - March 24, 2026) - Apolo V Acquisition Corp. (TSXV: AFV.P) ("Apolo V") is pleased to announce that it has filed its filing statement (the "Filing Statement") dated March 24, 2026 on its SEDAR+ profile in connection with the proposed business combination among Apolo V, TelyRx, Inc. ("TelyRx"), TelyRx Finco Inc. ("Finco"), 1001474388 Ontario Inc., and Apolo V MergerCo Inc. (the "Proposed Transaction"). In conjunction with, an
Soins de santé et hôpitaux, Santé
2026-03-24 8:33 PM EDT | TelyRx
Discovery Senior Living Establishes Chief Performance Officer Group to Drive NOI Expansion, Asset Optimization, and Predictive Performance Across National and Regional Communities
Bonita Springs, Florida--(Newsfile Corp. - March 24, 2026) - Discovery Senior Living ("Discovery" or the "Company") and its affiliated subsidiaries, one of the most trusted and the largest privately held senior housing operators in the U.S., is pleased to provide an update on its recently announced appointment of Tom Costello to Chief Performance Officer. This is a new role and functional group under Tom marking the next stage in the Company's platform evolution following the recent ap
Soins de santé et hôpitaux, Immobilier, Logement
2026-03-24 2:08 PM EDT | Discovery Senior Living
Tonight: Adia Nutrition and UCF CARD Host Live Zoom on Revolutionary Stem Cell Study for Autism - Strong Interest Already Building
Winter Park, Florida--(Newsfile Corp. - March 24, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine through its Adia Med division, is excited to announce a special virtual Zoom presentation happening tonight, Tuesday, March 24, 2026, at 6:00 PM EDT, with the Center for Autism and Related Disabilities (CARD) at the University of Central Florida (UCF). This high-impact session will deliver critical information directly to families, caregivers, and professionals
Soins de santé et hôpitaux, Santé
2026-03-24 8:00 AM EDT | Adia Nutrition Inc.
Envoy Medical Reports Full Year 2025 Financial Results
Received FDA approval to expand fully implanted Acclaim® Cochlear Implant Pivotal Clinical Trial to final stage Strengthened balance sheet by extinguishing $32 million in debt Subsequent to year-end, closed on transformational capital raise led by established institutional healthcare investors and completed enrollment of Pivotal Clinical Trial for first-of-its-kind fully impla
Biotechnologies, Soins de santé et hôpitaux
2026-03-23 8:30 AM EDT | Envoy Medical, Inc.
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement
King of Prussia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a podium presentation addressing its lead product candidate, PH-762, will be given in the American Academy of Dermatology's Late-Breaking Research Session S034 on March 28, 2026 in Denver, Col
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-23 7:00 AM EDT | Phio Pharmaceuticals Corp.
HEALWELL AI Delivers Record Revenue and First Year of Positive Adjusted EBITDA as Global AI Platform Strategy Takes Hold
Record revenue growth - HEALWELL achieved record annual revenue from continuing operations of approximately $103.8 million in fiscal 2025, an increase of 427% compared to the $19.7 million in fiscal 2024. The Company reported an IFRS net loss from continuing operations of $39.1 million in fiscal 2025, compared to a net loss of $24 million in fiscal 2024. First full year of positive Adjusted EBITDA - HEALWELL delivered Adjusted EBITDA o
Technologies, Soins de santé et hôpitaux
2026-03-19 7:00 AM EDT | HEALWELL AI
TIME Names medmix as one of "World's Best Companies for Sustainable Growth 2026"
medmix AG Neuhofstrasse 20 CH-6430 Baar communications@medmix.com www.medmix.swiss DOWNLOAD MEDIA RELEASE
Technologies, Construction / bâtiments, Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques
2026-03-18 4:07 AM EDT | medmix AG